Enterin is developing ENT-01, a drug that targets the dysfunctional gut-brain axis in patients with neurodegenerative diseases, specifically Parkinson's Disease. Preclinical studies show that ENT-01 displaces α-synuclein aggregates and significantly improves quality of life by restoring normal signaling between the gut and brain.
Funding
$60.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson's Disease and other neurodegenerative diseases are characterized by a dysfunctional gut-brain axis. This disruption impairs normal signaling between the gut and brain, leading to a decline in quality of life for affected individuals.
Solution
Enterin is developing ENT-01, a novel drug designed to repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Preclinical studies have demonstrated that ENT-01 effectively displaces α-synuclein aggregates, which are implicated in the pathogenesis of Parkinson's Disease. By restoring normal signaling between the gut and the brain, ENT-01 aims to improve the quality of life for patients suffering from these debilitating conditions. A Phase 2b study has shown that ENT-01 met its primary endpoint for patients with Parkinson's Disease.
Target Audience
The primary target audience includes patients diagnosed with Parkinson's Disease and other neurodegenerative diseases experiencing a dysfunctional gut-brain axis.
Features
- Targets the dysfunctional gut-brain axis to restore normal signaling.
- Designed to displace α-synuclein aggregates.
- Aims to improve quality of life by influencing non-motor symptoms.